Innoviva, INC. (INVA) — SEC Filings

Q: What are the key financial highlights for Innoviva, INC.?

Key financial highlights for Innoviva, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Innoviva, INC.?

Key executives at Innoviva, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Innoviva, INC. stock?

Risk factors for Innoviva, INC. (INVA) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Innoviva, INC.?

Forward-looking statements and predictions from Innoviva, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Innoviva, INC.. Recent 10-Q filing on Nov 5, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Innoviva, INC. on SEC EDGAR

Overview

Innoviva, INC. (INVA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Innoviva, Inc. reported a significant increase in net income for the three and nine months ended September 30, 2025, reaching $89.908 million and $107.012 million, respectively, compared to $1.213 million and $3.060 million in the prior year periods. Total revenue grew to $107.800 million for the th

Sentiment Summary

Across 34 filings, the sentiment breakdown is: 3 bullish, 31 neutral. The dominant filing sentiment for Innoviva, INC. is neutral.

Filing Type Overview

Innoviva, INC. (INVA) has filed 6 10-Q, 12 8-K, 2 DEF 14A, 3 10-K/A, 2 10-K, 2 SC 13D/A, 2 SC 13G, 1 SC 13D, 4 SC 13G/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (34)

Innoviva's Net Income Soars on Strong Product Sales, FDA Nod for Zoliflodacin — 10-Q · Nov 5, 2025 Risk: medium
Innoviva, Inc. reported a significant increase in net income for the three and nine months ended September 30, 2025, reaching $89.908 million and $107.012 milli
8-K Filing — 8-K · Nov 5, 2025
Innoviva, Inc. Files 8-K on Financials — 8-K · Aug 6, 2025 Risk: low
Innoviva, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhi
Innoviva's Q2 Earnings Soar on Strong Royalty Growth — 10-Q · Aug 6, 2025 Risk: medium
Innoviva, Inc. reported a significant increase in revenue for the three months ended June 30, 2025, reaching $68.5 million, up from $58.1 million in the prior-y
Innoviva, Inc. Reports on Shareholder Vote Matters — 8-K · May 21, 2025 Risk: low
Innoviva, Inc. filed an 8-K on May 21, 2025, reporting on matters submitted to a vote of its security holders on May 19, 2025. The filing details the company's
Innoviva, Inc. Files 8-K on Financials — 8-K · May 7, 2025 Risk: low
Innoviva, Inc. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibit
Innoviva 10-Q: Convertible Notes Focus — 10-Q · May 7, 2025 Risk: medium
Innoviva, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including details on its convertible notes.
Innoviva Inc. Files 2025 Proxy Statement — DEF 14A · Apr 8, 2025 Risk: low
Innoviva, Inc. filed its DEF 14A on April 8, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate g
Innoviva, Inc. Files 2024 Annual Report Amendment — 10-K/A · Mar 24, 2025 Risk: low
Innoviva, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on March 24, 2025, provides u
Innoviva, Inc. Files 8-K on Financials — 8-K · Feb 26, 2025 Risk: low
Innoviva, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and e
10-K Filing — 10-K · Feb 26, 2025
Innoviva Amends Stake in Armata Pharmaceuticals — SC 13D/A · Nov 14, 2024 Risk: medium
Innoviva, Inc. has filed an SC 13D/A amendment on November 14, 2024, related to Armata Pharmaceuticals, Inc. The filing indicates a change in beneficial ownersh
Innoviva, Inc. Files 8-K on Financials — 8-K · Nov 6, 2024 Risk: low
Innoviva, Inc. filed an 8-K on November 6, 2024, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and ex
Innoviva, Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 6, 2024 Risk: medium
Innoviva, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and business operations, including information
Innoviva, Inc. Files 8-K on Financials — 8-K · Jul 31, 2024 Risk: low
Innoviva, Inc. filed an 8-K on July 31, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhib
Innoviva Q2 2024 10-Q: Financials and Key Agreements — 10-Q · Jul 31, 2024 Risk: medium
Innoviva, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance, including revenues and liabilities. Key fi
Innoviva, Inc. Files 8-K on Shareholder Matters — 8-K · Jun 20, 2024 Risk: low
Innoviva, Inc. filed an 8-K on June 20, 2024, reporting on matters submitted to a vote of its security holders as of June 17, 2024. The filing details the compa
Innoviva, Inc. Files 8-K with SEC — 8-K · May 13, 2024 Risk: low
Innoviva, Inc. filed an 8-K on May 13, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific fi
SC 13G Filing — SC 13G · May 13, 2024
Innoviva, Inc. Files 8-K on Financials — 8-K · May 8, 2024 Risk: low
Innoviva, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibit
Franklin Resources Files 13D on Innoviva — SC 13D · May 8, 2024 Risk: medium
Franklin Resources Inc. has filed a Schedule 13D, indicating a change in its beneficial ownership of Innoviva, Inc. as of May 8, 2024. The filing details their
Innoviva, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: low
Innoviva, Inc. (INVA) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Innoviva, Inc. filed a 10-Q report for the period ending March 31, 2024. The
Innoviva Appoints New Directors, Discloses Officer Compensation — 8-K · Apr 30, 2024 Risk: low
Innoviva, Inc. announced on April 29, 2024, the appointment of Dr. Steven M. Altschuler and Ms. Jennifer L. Fox to its Board of Directors, effective immediately
Innoviva, Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 29, 2024 Risk: low
Innoviva, Inc. (INVA) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Innoviva, Inc. filed a DEF 14A form on April 29, 2024. The filing covers
Innoviva, Inc. Files Amendment No. 2 to 2023 Annual Report — 10-K/A · Mar 22, 2024 Risk: low
Innoviva, Inc. (INVA) filed a Amended Annual Report (10-K/A) with the SEC on March 22, 2024. Innoviva, Inc. filed an amendment (10-K/A) to its annual report for
Innoviva, Inc. Files 10-K/A Amendment for Fiscal Year 2023 — 10-K/A · Mar 5, 2024 Risk: low
Innoviva, Inc. (INVA) filed a Amended Annual Report (10-K/A) with the SEC on March 5, 2024. Innoviva, Inc. filed an amended 10-K for the fiscal year ending Dece
Innoviva, Inc. Files 13D/A Amendment on Armata Pharma — SC 13D/A · Mar 4, 2024 Risk: medium
Innoviva, Inc. has filed a Schedule 13D/A amendment on March 4, 2024, related to its beneficial ownership of Armata Pharmaceuticals, Inc. The filing indicates a
Innoviva, Inc. Files 8-K on Financials — 8-K · Feb 29, 2024 Risk: low
Innoviva, Inc. filed an 8-K on February 29, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and e
Innoviva, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: low
Innoviva, Inc. (INVA) filed a Annual Report (10-K) with the SEC on February 29, 2024. Innoviva, Inc. filed its annual report for the fiscal year ending December
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
Dimensional Fund Advisors Takes 5.0% Stake in Innoviva Inc. — SC 13G · Feb 9, 2024 Risk: low
Dimensional Fund Advisors LP, a major investment firm, reported on February 9, 2024, that it beneficially owns 5.0% of Innoviva, Inc.'s Common Stock as of Decem
BlackRock Updates Passive Stake in Innoviva Inc. (SC 13G/A) — SC 13G/A · Jan 22, 2024
BlackRock Inc. filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Innoviva Inc. common stock as of December 31, 2023. This filing, Amend

Risk Profile

Risk Assessment: Of INVA's 27 recent filings, 0 were flagged as high-risk, 8 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Innoviva, INC.'s most recent 10-Q filing (Nov 5, 2025):

Revenue: $296.715M
Net Income: $107.012M
EPS: N/A
Debt-to-Equity: 0.25
Cash Position: $476.513M
Operating Margin: N/A
Total Assets: $1,429.106M
Total Debt: $313.248M

Key Executives

Pavel Raifeld
Dr. Steven M. Altschuler
Ms. Jennifer L. Fox

Industry Context

Innoviva operates in the pharmaceutical and biotechnology sector, focusing on critical care and infectious diseases. The industry is characterized by high R&D costs, lengthy development cycles, stringent regulatory oversight, and significant competition. Recent trends include a focus on novel antibiotics to combat antimicrobial resistance and the strategic acquisition or in-licensing of late-stage assets to bolster pipelines.

Top Tags

8-k (8) · financial-reporting (6) · pharmaceuticals (6) · Innoviva (5) · Pharmaceuticals (3) · corporate-governance (3) · 10-Q (3) · amendment (3) · ownership-change (3) · Royalty Revenue (2)

Key Numbers

Net income for Q3 2025: $89.908M — Increased from $1.213M in Q3 2024, representing significant growth.
Net income for nine months ended Sept 30, 2025: $107.012M — Increased from $3.060M in the prior year period.
Total revenue for Q3 2025: $107.800M — Up from $89.508M in Q3 2024, indicating strong top-line performance.
Total revenue for nine months ended Sept 30, 2025: $296.715M — Up from $266.905M in the prior year period.
Net product sales for Q3 2025: $47.294M — Increased significantly from $27.822M in Q3 2024, driving revenue growth.
Net product sales for nine months ended Sept 30, 2025: $113.066M — Increased from $68.557M in the prior year period.
Royalty revenue for Q3 2025: $59.896M — Increased from $57.056M in Q3 2024, contributing to overall revenue.
Royalty revenue for nine months ended Sept 30, 2025: $181.583M — Increased from $179.213M in the prior year period.
Common stock outstanding: 74,769,062 — As of October 31, 2025, reflecting share issuance.
Cash and cash equivalents: $476.513M — As of September 30, 2025, up from $304.964M at December 31, 2024, indicating strong liquidity.
Total Revenue: $68.5M — Increased from $58.1 million in Q2 2024, driven by higher royalty revenues.
Net Income: $35.2M — Increased from $28.9 million in Q2 2024, reflecting strong operational performance.
Diluted EPS: $0.38 — Increased from $0.31 in Q2 2024.
Customer Concentration: 29% — One customer accounted for 29% of product revenue in 2024, indicating a risk.
Royalty Revenue from Paion AG: $1.5M — Recognized for the six months ended June 30, 2025.

Forward-Looking Statements

{"claim":"Innoviva Inc. stock may experience increased investor interest due to the institutional backing.","entity":"Innoviva Inc.","targetDate":"Q2 2024","confidence":"medium"}

Related Companies

GSK · ARMP · ARMATA

Frequently Asked Questions

What are the latest SEC filings for Innoviva, INC. (INVA)?

Innoviva, INC. has 34 recent SEC filings from Jan 2024 to Nov 2025, including 12 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of INVA filings?

Across 34 filings, the sentiment breakdown is: 3 bullish, 31 neutral. The dominant sentiment is neutral.

Where can I find Innoviva, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Innoviva, INC. (INVA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Innoviva, INC.?

Key financial highlights from Innoviva, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for INVA?

The investment thesis for INVA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Innoviva, INC.?

Key executives identified across Innoviva, INC.'s filings include Pavel Raifeld, Dr. Steven M. Altschuler, Ms. Jennifer L. Fox.

What are the main risk factors for Innoviva, INC. stock?

Of INVA's 27 assessed filings, 0 were flagged high-risk, 8 medium-risk, and 19 low-risk.

What are recent predictions and forward guidance from Innoviva, INC.?

Recent forward-looking statements from Innoviva, INC. include guidance on {"claim":"Innoviva Inc. stock may experience increased investor interest due to the institutional backing.","entity":"In.